These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Na+-dependent SR Ca2+ overload induces arrhythmogenic events in mouse cardiomyocytes with a human CPVT mutation. Sedej S; Heinzel FR; Walther S; Dybkova N; Wakula P; Groborz J; Gronau P; Maier LS; Vos MA; Lai FA; Napolitano C; Priori SG; Kockskämper J; Pieske B Cardiovasc Res; 2010 Jul; 87(1):50-9. PubMed ID: 20080988 [TBL] [Abstract][Full Text] [Related]
3. Arrhythmogenesis in a catecholaminergic polymorphic ventricular tachycardia mutation that depresses ryanodine receptor function. Zhao YT; Valdivia CR; Gurrola GB; Powers PP; Willis BC; Moss RL; Jalife J; Valdivia HH Proc Natl Acad Sci U S A; 2015 Mar; 112(13):E1669-77. PubMed ID: 25775566 [TBL] [Abstract][Full Text] [Related]
4. Cell model of catecholaminergic polymorphic ventricular tachycardia reveals early and delayed afterdepolarizations. Kujala K; Paavola J; Lahti A; Larsson K; Pekkanen-Mattila M; Viitasalo M; Lahtinen AM; Toivonen L; Kontula K; Swan H; Laine M; Silvennoinen O; Aalto-Setälä K PLoS One; 2012; 7(9):e44660. PubMed ID: 22962621 [TBL] [Abstract][Full Text] [Related]
5. Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia. Jung CB; Moretti A; Mederos y Schnitzler M; Iop L; Storch U; Bellin M; Dorn T; Ruppenthal S; Pfeiffer S; Goedel A; Dirschinger RJ; Seyfarth M; Lam JT; Sinnecker D; Gudermann T; Lipp P; Laugwitz KL EMBO Mol Med; 2012 Mar; 4(3):180-91. PubMed ID: 22174035 [TBL] [Abstract][Full Text] [Related]
6. Prevention of ventricular arrhythmia and calcium dysregulation in a catecholaminergic polymorphic ventricular tachycardia mouse model carrying calsequestrin-2 mutation. Alcalai R; Wakimoto H; Arad M; Planer D; Konno T; Wang L; Seidman JG; Seidman CE; Berul CI J Cardiovasc Electrophysiol; 2011 Mar; 22(3):316-24. PubMed ID: 20807279 [TBL] [Abstract][Full Text] [Related]
7. Calsequestrin 2 (CASQ2) mutations increase expression of calreticulin and ryanodine receptors, causing catecholaminergic polymorphic ventricular tachycardia. Song L; Alcalai R; Arad M; Wolf CM; Toka O; Conner DA; Berul CI; Eldar M; Seidman CE; Seidman JG J Clin Invest; 2007 Jul; 117(7):1814-23. PubMed ID: 17607358 [TBL] [Abstract][Full Text] [Related]
8. Targeting intracellular calcium cycling in catecholaminergic polymorphic ventricular tachycardia: a theoretical investigation. Sung RJ; Lo CP; Hsiao PY; Tien HC Am J Physiol Heart Circ Physiol; 2011 Oct; 301(4):H1625-38. PubMed ID: 21742998 [TBL] [Abstract][Full Text] [Related]
9. Molecular, Subcellular, and Arrhythmogenic Mechanisms in Genetic RyR2 Disease. Fowler ED; Zissimopoulos S Biomolecules; 2022 Jul; 12(8):. PubMed ID: 35892340 [TBL] [Abstract][Full Text] [Related]
10. EL20, a potent antiarrhythmic compound, selectively inhibits calmodulin-deficient ryanodine receptor type 2. Klipp RC; Li N; Wang Q; Word TA; Sibrian-Vazquez M; Strongin RM; Wehrens XHT; Abramson JJ Heart Rhythm; 2018 Apr; 15(4):578-586. PubMed ID: 29248564 [TBL] [Abstract][Full Text] [Related]
11. Calcium leak through ryanodine receptors leads to atrial fibrillation in 3 mouse models of catecholaminergic polymorphic ventricular tachycardia. Shan J; Xie W; Betzenhauser M; Reiken S; Chen BX; Wronska A; Marks AR Circ Res; 2012 Aug; 111(6):708-17. PubMed ID: 22828895 [TBL] [Abstract][Full Text] [Related]